Scarica l'app Stockscreener
72.83
2.77%
1.96
Pre-mercato:
71.89
-0.94
-1.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca PLC Borsa (AZN) Ultime notizie
AstraZeneca: promising results for Imfinzi in gastric cancer - marketscreener.com
AstraZeneca: camizestrant effective in breast cancer - marketscreener.com
AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth - NDTV Profit
PRESS DIGEST- Financial TimesJune 2 - marketscreener.com
AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News - GuruFocus
AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News - GuruFocus
AstraZeneca breast cancer medicine slows disease by over six months - The Economic Times
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk - marketscreener.com
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive
AstraZeneca drug could help keep a common breast cancer at bay - BioPharma Dive
IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial - marketscreener.com
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds - marketscreener.com
AstraZeneca Breast Cancer Pill Slows Disease by Over Six Months - Bloomberg.com
AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit - Bloomberg Law News
AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action - Reuters
Danaher Partners With AstraZeneca to Support Precision Medicine - TradingView
AstraZeneca - Britannica
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools - marketscreener.com
Barclays Remains Upbeat on AstraZeneca, Expects US Conference to Highlight Breast Cancer Franchise - marketscreener.com
AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India - Medical Dialogues
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests - Yahoo Finance
AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case - Law360
Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine (DHR:NYSE) - Seeking Alpha
Danaher partners with AstraZeneca on AI diagnostics By Investing.com - Investing.com Nigeria
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - Yahoo Finance
Transcript : AstraZeneca PLCSpecial Call - marketscreener.com
AstraZeneca and Global Transparency - AstraZeneca
Ethics and Compliance - AstraZeneca
Nature - AstraZeneca
Inclusion and diversity - AstraZeneca
Community investment - AstraZeneca
AstraZeneca (AZN) Collaborates on Major AI Infrastructure in Swe - GuruFocus
AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47% - MSN
AstraZeneca (AZN) Executive Joins Rapid Micro Biosystems' Board | AZN Stock News - GuruFocus
AstraZeneca (AZN) Gains EU Panel Support for Imfinzi in Bladder Cancer - GuruFocus
AstraZeneca (AZN) Nears EU Approval for Imfinzi in Bladder Cance - GuruFocus
AstraZeneca wins EU backing for Imfinzi in bladder cancer - Seeking Alpha
AstraZeneca Gains Positive Opinion for Imfinzi's Bladder Cancer Indication in EU - marketscreener.com
AstraZeneca: CHMP gives positive opinion for Imfinzi - marketscreener.com
EU recommends AstraZeneca bladder cancer treatment for approval - Sharecast.com
AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer - DirectorsTalk Interviews
AstraZeneca's Imfinzi Wins EU Approval Recommendation for Bladder Cancer - marketscreener.com
AstraZeneca Says Imfinzi Recommended In EU For Bladder Cancer - marketscreener.com
ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com
AstraZeneca (AZN) Partners in Sweden's Largest AI Supercomputer Initiative | AZN Stock News - GuruFocus
Gouty Arthritis Market Overall Study Report 2025-2032 | - openPR.com
AstraZeneca PLC (NASDAQ:AZN) Given Average Recommendation of “Buy” by Brokerages - Defense World
AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Call Transcript - MSN
Why AstraZeneca May Be 2025’s Most Underrated Pharma Stock (NASDAQ:AZN) - Seeking Alpha
Astrazeneca's Imfinzi Gets Expanded EU Committee Recommendation to Include Muscle Invasive Bladder Cancer - marketscreener.com
AstraZeneca CEO gains shares under performance plan - Investing.com
AstraZeneca: commercial discussions with Induct AS - marketscreener.com
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
AstraZeneca’s SWOT analysis: pipeline strength fuels stock potential - Investing.com
Sandoz Ordered To Recall Diabetes Drug In AstraZeneca Fight - Law360
Ciclesonide Market Rising Demand and Growth Forecast Through - openPR.com
AstraZeneca PLC : The comeback of an upward trend can be anticipated - marketscreener.com
AstraZeneca CEO joins Agilent Board By Investing.com - Investing.com South Africa
AstraZeneca Stock Declines 6% In 3 Months: Time To Buy The Dip? - Barchart.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):